cross-posted from: https://lemmy.ca/post/48067393

A very detailed guide on the privacy implications of Mastodon (how it's better and what to look out for)

A very detailed guide on the privacy implications of Mastodon (how it's better and what to look out for)

A sweeping analysis of health data from more than 1.2 million children in Denmark born over a 24-year period found no link between the small amounts of aluminum in vaccines and a wide range of health conditions—including asthma, allergies, eczema, autism, and attention deficit-hyperactivity disorder (ADHD).

The finding, published in the Annals of Internal Medicine, firmly squashes a persistent anti-vaccine talking point that can give vaccine-hesitant parents pause.

Small amounts of aluminum salts have been added to vaccines for decades as adjuvants, that is, components of the vaccine that help drum up protective immune responses against a target germ. Aluminum adjuvants can be found in a variety of vaccines, including those against diphtheria, tetanus, and pertussis, Haemophilus influenzae type b (Hib), and hepatitis A and B.

Despite decades of use worldwide and no clear link to harms, concern about aluminum and cumulative exposures continually resurfaces—largely thanks to anti-vaccine advocates who fearmonger about the element. A leader of such voices is Robert F. Kennedy Jr, the current US health secretary and an ardent anti-vaccine advocate.

In a June 2024 interview with podcaster Joe Rogan, Kennedy falsely claimed that aluminum is "extremely neurotoxic" and "give[s] you allergies." The podcast has racked up nearly 2 million views on YouTube. Likewise, Children's Health Defense, the rabid anti-vaccine organization Kennedy created in 2018, has also made wild claims about the safety of aluminum adjuvants. That includes linking it to autism, despite that many high-quality scientific studies have found no link between any vaccines and autism.

While anti-vaccine advocates like Kennedy routinely dismiss and attack the plethora of studies that do not support their dangerous claims, the new study should reassure any hesitant parents.

Source: https://poorlydrawnlines.com/comic/wizard/

Injectable prescription drugs, sold as Ozempic and Wegovy, and the pill Rybelsus all contain the ingredient semaglutide. This class of medication, known as glucagon-like peptide-1 (GLP-1s), regulate blood sugar levels and appetite.

Health Canada previously approved Ozempic to treat diabetes and Wegovy for weight loss. Nearly 33 per cent of Canadians (10.6 million people) were obese in 2023, according to a recent study.

Novo Nordisk, maker of Ozempic and Wegovy, will effectively lose its price protection on those drugs in Canada in January, opening the door to generic versions.

Mina Tadrous, an associate professor who evaluates pharmaceutical prices at the University of Toronto, says three or four companies have them in development or are starting the paperwork.

Tadrous says the number of companies affects pricing.

"The classic framework is that if you only have one, it comes down from the list price to 75 per cent," Tadrous said. "If we have two, it goes down to 50 per cent and if we have three it hits 25 per cent."

Three manufacturers could bring the price down to $100 from $400 for the same strength of semaglutide product, Tadrous estimates.

Injectable prescription drugs, sold as Ozempic and Wegovy, and the pill Rybelsus all contain the ingredient semaglutide. This class of medication, known as glucagon-like peptide-1 (GLP-1s), regulate blood sugar levels and appetite.

Health Canada previously approved Ozempic to treat diabetes and Wegovy for weight loss. Nearly 33 per cent of Canadians (10.6 million people) were obese in 2023, according to a recent study.

Novo Nordisk, maker of Ozempic and Wegovy, will effectively lose its price protection on those drugs in Canada in January, opening the door to generic versions.

Mina Tadrous, an associate professor who evaluates pharmaceutical prices at the University of Toronto, says three or four companies have them in development or are starting the paperwork.

Tadrous says the number of companies affects pricing.

"The classic framework is that if you only have one, it comes down from the list price to 75 per cent," Tadrous said. "If we have two, it goes down to 50 per cent and if we have three it hits 25 per cent."

Three manufacturers could bring the price down to $100 from $400 for the same strength of semaglutide product, Tadrous estimates.

Source: https://xkcd.com/3112/

Source: https://thejenkinscomic.wordpress.com/2025/07/10/programming-in-2035/

Source: https://xkcd.com/3114/

cross-posted from: https://lemmy.ca/post/47966225

The update:

After months of hard work, we're thrilled to release the first beta for Lawnchair 15. This is a massive, foundational update based on Android 15.

The headline feature is one you've all been waiting for: App Drawer Folders! You can now create and reorder custom folders to organize your app drawer exactly how you want.

This release also includes a huge number of under-the-hood improvements, UI refinements, and new customization options.

Read the full story and see what's new on our blog: https://lawnchair.app/blog/lawnchair-15-beta-1

Download Lawnchair 15 Beta 1 from GitHub: https://github.com/LawnchairLauncher/lawnchair/releases/tag/v15.0.0-beta1

Thank you for your incredible support!

The update:

After months of hard work, we're thrilled to release the first beta for Lawnchair 15. This is a massive, foundational update based on Android 15.

The headline feature is one you've all been waiting for: App Drawer Folders! You can now create and reorder custom folders to organize your app drawer exactly how you want.

This release also includes a huge number of under-the-hood improvements, UI refinements, and new customization options.

Read the full story and see what's new on our blog: https://lawnchair.app/blog/lawnchair-15-beta-1

Download Lawnchair 15 Beta 1 from GitHub: https://github.com/LawnchairLauncher/lawnchair/releases/tag/v15.0.0-beta1

Thank you for your incredible support!